GlobeNewswire by notified

Diabetes Leadership Council Names Congresswoman Diana DeGette, Senator Susan Collins and Senator Jeanne Shaheen as 2022 Diabetes Champions

Share

WASHINGTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- The Diabetes Leadership Council (DLC), a diabetes and health care reform advocacy organization advancing patient-centered policies at the local, state and federal levels, today announced Congresswoman Diana DeGette, Senator Susan Collins and Senator Jeanne Shaheen as its 2022 Diabetes Champions.

“Through their leadership of the Diabetes Caucus and Congressional efforts to reduce insulin costs, Congresswoman DeGette, Senators Collins and Shaheen truly demonstrate a commitment to the 37 million Americans living with diabetes,” said Stewart Perry, Board Chair, Diabetes Leadership Council. “We are proud to recognize them for their dedication and hope their example of ‘Less Talk, More Action’ inspires other members of Congress who pay lip service to our cause but fail to act.”

“As the mother of a daughter with Type-I diabetes, I know firsthand the struggles that millions of Americans face on a daily basis because of this disease,” said DeGette, “and it’s why I remain determined to help find new ways to treat, and eventually cure, this devastating illness. Diseases such as diabetes don’t care if you’re a Democrat or Republican, they affect all of us the same. While we have made significant progress over the years to help the millions of Americans living with diabetes, there’s still a lot more we can do. And I am confident that by working together we can get a lot more done.”

“As the founder and co-chair of the Senate Diabetes Caucus, I have long worked to increase funding for biomedical research, which has produced revolutionary treatment options for those who are affected by this disease. I am also committed to supporting federal policies that will help improve the lives of patients and their families,” said Senator Collins. “The Diabetes Leadership Council is a powerful and effective voice for diabetes patients. I am honored to receive this recognition, and I will continue to build on the progress we have made to better treat, prevent, and ultimately cure diabetes.”

“I’m honored to be named as one of the Diabetes Leadership Council’s 2022 Diabetes Champions. Far too often, Americans living with diabetes are forced to make difficult financial and personal decisions to access insulin and other life-sustaining medications and treatments. That’s unacceptable,” said Shaheen. “In order to ensure affordable access to diabetes care is within reach, it's imperative we continue to fight towards reducing the high cost of insulin and extending patient protections. Through my work as co-chair of the Senate Diabetes Caucus, I’ll keep advocating for federal action to address this issue and bring about much-needed relief for the millions of Americans and their families impacted by this chronic condition.”

About the Diabetes Leadership Council Champion Award:

The Diabetes Leadership Council presents the award to the most effective lawmakers based on their public commitment and legislative actions to increase health care access and affordability for Americans with chronic health conditions, particularly the 37 million individuals living with diabetes and 90 million who have pre-diabetes.

About Congresswoman DeGette:

Congresswoman DeGette represents Colorado’s first district and is the Democratic co-chair of the Congressional Diabetes Caucus. She is also the chair of the Energy and Commerce Oversight and Investigations Subcommittee, which directly oversees the nation’s health industry. In the 117th Congress, Congresswoman DeGette also leads efforts on Cures 2.0 and the Advanced Research Projects Agency for Health (ARPA-H) to accelerate the delivery of groundbreaking and lifesaving cures, treatments and innovations aimed at ending some of the world’s most difficult diseases. Along with fellow award winners, Congresswoman DeGette continues to support health care affordability beyond insulin by supporting Medicare coverage of continuous glucose monitoring (CGM) and other medical devices crucial to the management of diabetes.

About Senator Collins:

Senator Collins represents the state of Maine. She sits on the Senate Committees on Appropriations and Health, Education, Labor and Pensions. In the 117th Congress, Senator Collins along with Senator Jeanne Shaheen has spearheaded the INSULIN Act, which seeks to reduce list prices of insulin while extending patient protections that will foster competition and broader access to insulin products. In addition to her efforts to support insulin affordability, Senator Collins continues to support improved Medicare coverage of Continuous Glucose Monitoring (CGM) and other devices that play a crucial role in diabetes care. 

About Senator Shaheen:

Senator Shaheen represents the state of New Hampshire. She sits on the Senate Appropriations Committee. In the 117th Congress, Senator Shaheen along with Senator Susan Collins has spearheaded the INSULIN Act, which seeks to increase measures to reduce list prices of insulin while extending patient protections that will foster competition and broader access to desperately needed insulin products. In addition to her efforts to support insulin affordability, Senator Shaheen continues to support improved Medicare coverage of Continuous Glucose Monitoring (CGM) and other devices that play a crucial role in diabetes care.

###

DLC is a 501(c)(3) patient advocacy organization comprised of individuals who combine their passion for advocacy with decades of diabetes experience and leadership to advance patients-first policies at the local, state and national levels. Our members – all former leaders of national diabetes organizations – engage policymakers, and public and private sector influencers to call attention to the diabetes epidemic and provide a voice for 37 million Americans living with the disease

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Summary Notice of Pendency and Proposed Settlement of Shareholder Derivative Actions3.5.2024 22:39:16 CEST | Press release

CUPERTINO, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Apple Inc. has released the following notice: A Federal Court authorized this Notice. This is not a solicitation from a lawyer. TO: ALL PERSONS OR ENTITIES WHO OR WHICH HELD SHARES OF APPLE INC. (“APPLE” OR THE “COMPANY”) COMMON STOCK AS OF THE CLOSE OF TRADING ON APRIL 29, 2024. THIS NOTICE RELATES TO THE PENDENCY AND PROPOSED SETTLEMENT OF SHAREHOLDER DERIVATIVE LITIGATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. IF YOU ARE A CURRENT APPLE SHAREHOLDER, THIS NOTICE CONTAINS IMPORTANT INFORMATION ABOUT YOUR RIGHTS. THIS ACTION IS NOT A “CLASS ACTION.” THUS, THERE IS NO COMMON FUND UPON WHICH YOU CAN MAKE A CLAIM FOR MONETARY PAYMENT. IF YOU DO NOT OBJECT TO THE TERMS OF THE PROPOSED SETTLEMENT OR THE AMOUNT OF ATTORNEYS’ FEES AND EXPENSES DESCRIBED IN THIS NOTICE, YOU ARE NOT OBLIGATED TO TAKE ANY ACTION. The purpose of this Notice is to inform you of: (i) the pendency of the shareholder derivative action brought on beh

CNH announces voting results of 2024 Annual General Meeting and publishes 2023 Sustainability Report3.5.2024 22:30:00 CEST | Press release

Basildon, May 3, 2024 CNH Industrial N.V. (NYSE: CNHI) today held its annual general meeting of shareholders. Shareholders re-appointed the Company’s director nominees, including Suzanne Heywood and Scott W. Wine as executive directors1, and Elizabeth Bastoni, Howard W. Buffett, Richard J. Kramer, Karen Linehan, Alessandro Nasi, Vagn Sørensen and Åsa Tamsons as non-executive directors. Shareholders also approved a dividend of $0.47 per common share (equivalent to a total distribution of approximately $585 million), and the AGM approved the Company’s Remuneration Policy. In other voting, shareholders appointed Deloitte Accountants B.V. as the independent auditor for the 2025 financial year and approved the Company’s 2023 financial statements prepared under IFRS. Details of all matters approved today by the AGM are available on the Company's website (www.cnh.com). *** The dividend is payable on May 29, 2024 to shareholders of record on May 13, 2024. Shareholders holding CNH common shares

Nokia Corporation: Repurchase of own shares on 03.05.20243.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 03 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 03.05.2024 Espoo, Finland – On 03 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL379,8083.44CEUX--BATE--AQEU--TQEX--Total379,8083.44 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons3.5.2024 19:48:16 CEST | Press release

Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar2 Reason for the notificationa)Position/statusExecutive Vice Presidentb)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN342

Subsea 7 S.A. notification of major holding3.5.2024 18:32:01 CEST | Press release

Luxembourg –3 May 2024 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced that, on 3 May 2024, Barclays Capital Securities Limited1 informed the Company that it had breached thresholds provided for by Luxembourg’s Transparency Law of 11 January 2008 on transparency requirements for issuers of securities as amended (the “Transparency Law”) as follows: On 30 April 2024 the total number of voting rights in the Company according to Article 8 and 9 of the Transparency Law attached to shares was 1,044,272 On 30 April 2024 the total number of voting rights in the Company attached to financial instruments with similar economic effect according to Article 12 (1) (a) of the Transparency Law (right to recall) was 13,906,019On 30 April 2024 the total number of voting rights in the Company attached to financial instruments with similar economic effect according to Article 12 (1) (b) of the Transparency Law (swaps) was 499,740 When combined, the above positions equate to 5.07% of voting r

HiddenA line styled icon from Orion Icon Library.Eye